Bristol-Myers Squibb Company (BMY)

55.67
NYSE : Health Care
Prev Close 55.67
Day Low/High 0.00 / 0.00
52 Wk Low/High 46.01 / 77.12
Avg Volume 10.75M
Exchange NYSE
Shares Outstanding 1.65B
Market Cap 88.59B
EPS 2.70
P/E Ratio 20.29
Div & Yield 1.56 (2.90%)

Latest News

PayPal Propels Nasdaq to New Record; Dow and S&P 500 Post Small Gains

PayPal Propels Nasdaq to New Record; Dow and S&P 500 Post Small Gains

Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.

Bristol-Myers Squibb To Take Part In Deutsche Bank Annual Health Care Conference

Bristol-Myers Squibb To Take Part In Deutsche Bank Annual Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the 42 nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017, in Boston.

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2017, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approval for Opdivo in...

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.

Rally Comes With Reasons for Concern

Rally Comes With Reasons for Concern

S&P is already at resistance levels, where the advance appeared to stall.

Transgene And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate TG4010 In Combination With Opdivo And Standard Chemotherapy In First Line Non-Small Cell Lung Cancer

Transgene And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate TG4010 In Combination With Opdivo And Standard Chemotherapy In First Line Non-Small Cell Lung Cancer

Regulatory News: Bristol-Myers Squibb Company (NYSE: BMY) and Transgene (Paris:TNG) today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene's...

Transgene And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate TG4010 In Combination With Opdivo And Standard Chemotherapy In First Line Non-Small Cell Lung Cancer

Transgene And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate TG4010 In Combination With Opdivo And Standard Chemotherapy In First Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) and Transgene today announced a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene's investigational therapeutic vaccine TG4010...

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement In Liver Fat, Liver Injury And Fibrosis In Patients With Nonalcoholic Steatohepatitis (NASH) In Phase 2 Trial

Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement In Liver Fat, Liver Injury And Fibrosis In Patients With Nonalcoholic Steatohepatitis (NASH) In Phase 2 Trial

Bristol-Myers Squibb Company (NYSE:BMY) today announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in...

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the...

Intermediate Trade: Bristol-Myers Squibb

Intermediate Trade: Bristol-Myers Squibb

Consider this BMY bullishly biased, near-the-money vertical call spread.

Bristol-Myers Squibb And Nordic Bioscience Announce Collaboration For Fibrosis Biomarker Technology

Bristol-Myers Squibb And Nordic Bioscience Announce Collaboration For Fibrosis Biomarker Technology

Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in...

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), from...

Bristol-Myers Squibb Enters Into Separate Agreements With Biogen And Roche To License Anti-eTau And Anti-Myostatin Compounds, Respectively

Bristol-Myers Squibb Enters Into Separate Agreements With Biogen And Roche To License Anti-eTau And Anti-Myostatin Compounds, Respectively

Bristol-Myers Squibb Company  (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to...

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said.

Whole Foods Shares Spike Under Pressure from Jana

Whole Foods Shares Spike Under Pressure from Jana

The activist investor launched an insurgency campaign at the organic grocer, seeking to press the company to consider strategic options and make other share-price improving changes.

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

'These companies are all assessing the Trump effect,' Cramer said.